1. A therapeutic combination comprising an effective amounts of first an ileal bile acid transport inhibiting compound and a second compound that is a nicotinic acid or nicotinic acid derivative wherein the amounts of the first and the second together comprise an anti-hyperlipidemic condition effective amount of the compounds and wherein said ileal bile acid transport inhibiting compound is represented by formula (B-5): or enantiomers, racemates or a pharmaceutically acceptable salt thereof. 2. The therapeutic combination of claim 1 wherein the nicotinic acid or nicotinic acid derivative is selected from the group comprising nicotinic acid, niceritrol, acipimox or a pharmaceutically acceptable salt thereof. 3. The therapeutic combination of claim 1 wherein the nicotinic acid or nicotinic acid derivative is a nicotinic acid or a pharmaceutically acceptable salt thereof. 4. The therapeutic combination of claim 1 wherein nicotinic acid or nicotinic acid derivative is a niceritrol or a pharmaceutically acceptable salt thereof. 5. The therapeutic combination of claim 1 wherein nicotinic acid or nicotinic acid derivative is an acipimox or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising an effective amount of first an ileal bile acid transport inhibiting compound and a second compound that is a nicotinic acid or nicotinic acid derivative wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount of the compounds, the first amount is about 0.01 to about 1000 mg, and the second amount is about 0.01 to about 10000 mg, and wherein the ileal bile acid transport inhibiting compound has the structure of formula B-5: or an enantiomer, racemate or pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition of claim 6 wherein the nicotinic acid or nicotinic acid derivative is selected from the group comprising nicotinic acid, niceritrol, acipimox or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition of claim 6 wherein the nicotinic acid or nicotinic acid derivative is a nicotinic acid or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition of claim 6 wherein nicotinic acid or nicotinic acid derivative is a niceritrol or a pharmaceutically acceptable salt thereof. 10. The pharmaceutical composition of claim 6 wherein nicotinic acid or nicotinic acid derivative is an acipimox or a pharmaceutically acceptable salt thereof. 11. A method for the prophylaxis or treatment of a hyperlipidemic condition comprising administering to a patient in need thereof a combination in unit dosage form wherein the combination comprises an effective amounts of a first ileal bile acid transport inhibiting compound and a second compound that is nicotinic acid or nicotinic acid derivative wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount of the compounds, wherein said ileal bile acid transport inhibiting compound is represented by formula (B-5): or enantiomers or racemates thereof. 12. The method of claim 11 wherein the daily dose range is from 0.01 to about 1000 mg of the ileal bile acid transport inhibiting compound one and from about 0.01 to about 10000 mg of nicotinic acid or nicotinic acid derivative. 13. The method of claim 11 wherein the wherein the hyperlipidemic condition is an atherosclerotic condition. 14. The method of claim 11 wherein the wherein the hyperlipidemic condition is hypercholesterolemia. 15. The method of claim 11 wherein nicotinic acid or nicotinic acid derivative is selected from the group comprising nicotinic acid or nicotinic acid derivative, acipimox, niceritrol or a pharmaceutically acceptable salt thereof. 16. The method of claim 11 wherein nicotinic acid or nicotinic acid derivative is nicotinic acid or a pharmaceutically acceptable salt thereof. 17. The method of claim 11 wherein nicotinic acid or nicotinic acid derivative is a niceritrol or a pharmaceutically acceptable salt thereof. 18. The method of claim 11 wherein nicotinic acid or nicotinic acid derivative is an acipimox or a pharmaceutically acceptable salt thereof.